Cash boost for SpectRx' cervical cancer detector:
This article was originally published in Clinica
SpectRx is to accelerate its programme to develop a non-invasive cervical cancer detection device, after receiving a $1.4m grant award from the US National Cancer Institute. The grant will be primarily used to help fund the pivotal clinical trials necessary for approval to market the biophotonic device in the US. The Norcross, Georgia firm said that the trials would start within 90 days.
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.